{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:09:39Z","timestamp":1786590579611,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Medical faculty of Tuebingen, Germany","award":["477-0-0"],"award-info":[{"award-number":["477-0-0"]}]},{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40291-024-00730-0","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T10:02:31Z","timestamp":1722333751000},"page":"593-600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Future of CAR T Therapeutics to Treat Autoimmune Disorders"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0201-0686","authenticated-orcid":false,"given":"Ann-Christin","family":"Pecher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-8537","authenticated-orcid":false,"given":"Luca","family":"Hensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-2805","authenticated-orcid":false,"given":"Claudia","family":"Lengerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8385-6861","authenticated-orcid":false,"given":"J\u00f6rg","family":"Henes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"issue":"1 Pt 1","key":"730_CR1","first-page":"127","volume":"21","author":"G Gross","year":"1989","unstructured":"Gross G, Gorochov G, Waks T, Eshhar Z. Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc. 1989;21(1 Pt 1):127\u201330.","journal-title":"Transplant Proc"},{"issue":"3","key":"730_CR2","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/0006-291x(87)90502-x","volume":"149","author":"Y Kuwana","year":"1987","unstructured":"Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun. 1987;149(3):960\u20138. https:\/\/doi.org\/10.1016\/0006-291x(87)90502-x.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"730_CR3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kronke G, Volkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-Targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385(6):567\u20139. https:\/\/doi.org\/10.1056\/NEJMc2107725.","journal-title":"N Engl J Med"},{"issue":"10","key":"730_CR4","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, Muller F, Mougiakakos D, Boltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124\u201332. https:\/\/doi.org\/10.1038\/s41591-022-02017-5.","journal-title":"Nat Med"},{"issue":"10379","key":"730_CR5","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","volume":"401","author":"F Muller","year":"2023","unstructured":"Muller F, Boeltz S, Knitza J, Aigner M, Volkl S, Kharboutli S, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023;401(10379):815\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(23)00023-5.","journal-title":"Lancet"},{"issue":"24","key":"730_CR6","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"AC Pecher","year":"2023","unstructured":"Pecher AC, Hensen L, Klein R, Schairer R, Lutz K, Atar D, et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA. 2023;329(24):2154\u201362. https:\/\/doi.org\/10.1001\/jama.2023.8753.","journal-title":"JAMA"},{"issue":"8","key":"730_CR7","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","volume":"82","author":"C Bergmann","year":"2023","unstructured":"Bergmann C, Muller F, Distler JHW, Gyorfi AH, Volkl S, Aigner M, et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis. 2023;82(8):1117\u201320. https:\/\/doi.org\/10.1136\/ard-2023-223952.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"730_CR8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit V, Benatar M, Kurtoglu M, Miljkovic MD, Chahin N, Sahagian G, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol. 2023;22(7):578\u201390. https:\/\/doi.org\/10.1016\/S1474-4422(23)00194-1.","journal-title":"Lancet Neurol"},{"issue":"8","key":"730_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Volkl S, et al. CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up. N Engl J Med. 2024;390(8):687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917.","journal-title":"N Engl J Med"},{"issue":"12","key":"730_CR10","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia A, Hegelmaier T, Wolleschak D, Bottcher M, Desel C, Borie D, et al. Anti-CD19 CAR T cells for refractory myasthenia gravis. Lancet Neurol. 2023;22(12):1104\u20135. https:\/\/doi.org\/10.1016\/S1474-4422(23)00375-7.","journal-title":"Lancet Neurol"},{"issue":"1","key":"730_CR11","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","volume":"63","author":"J Taubmann","year":"2024","unstructured":"Taubmann J, Knitza J, Muller F, Volkl S, Aigner M, Kleyer A, et al. Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies. Rheumatology (Oxford). 2024;63(1):e12\u20134. https:\/\/doi.org\/10.1093\/rheumatology\/kead330.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"730_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/ard-2023-225174","volume":"83","author":"W Merkt","year":"2024","unstructured":"Merkt W, Freitag M, Claus M, Kolb P, Falcone V, Rohrich M, et al. Third-generation CD19. CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis. Ann Rheum Dis. 2024;83(4):543\u20136. https:\/\/doi.org\/10.1136\/ard-2023-225174.","journal-title":"Ann Rheum Dis"},{"key":"730_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.03.002","author":"F Fischbach","year":"2024","unstructured":"Fischbach F, Richter J, Pfeffer LK, Fehse B, Berger SC, Reinhardt S, et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. 2024. https:\/\/doi.org\/10.1016\/j.medj.2024.03.002.","journal-title":"Med"},{"issue":"1","key":"730_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","volume":"8","author":"C Qin","year":"2023","unstructured":"Qin C, Tian DS, Zhou LQ, Shang K, Huang L, Dong MH, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther. 2023;8(1):5. https:\/\/doi.org\/10.1038\/s41392-022-01278-3.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"730_CR15","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s41409-023-01957-x","volume":"58","author":"N Worel","year":"2023","unstructured":"Worel N, Holbro A, Vrielink H, Ootjers C, Le Poole K, Beer-Wekking I, et al. A guide to the collection of T-cells by apheresis for ATMP manufacturing-recommendations of the GoCART coalition apheresis working group. Bone Marrow Transplant. 2023;58(7):742\u20138. https:\/\/doi.org\/10.1038\/s41409-023-01957-x.","journal-title":"Bone Marrow Transplant"},{"issue":"7949","key":"730_CR16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614(7949):635\u201348. https:\/\/doi.org\/10.1038\/s41586-023-05707-3.","journal-title":"Nature"},{"issue":"3","key":"730_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367. https:\/\/doi.org\/10.1038\/s41571-019-0297-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"730_CR18","doi-asserted-by":"crossref","unstructured":"Mohty M, Minnema MC. Lymphodepleting conditioning regimens. In: Kroger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors. The EBMT\/EHA CAR-T cell handbook. Springer Cham; 2022. p. 131\u20133.","DOI":"10.1007\/978-3-030-94353-0_25"},{"issue":"10","key":"730_CR19","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","volume":"57","author":"K Wudhikarn","year":"2022","unstructured":"Wudhikarn K, Perales MA. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transplant. 2022;57(10):1477\u201388. https:\/\/doi.org\/10.1038\/s41409-022-01756-w.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"730_CR20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/cid\/ciaa127","volume":"72","author":"S Stabler","year":"2021","unstructured":"Stabler S, Giovannelli J, Launay D, Cotteau-Leroy A, Heusele M, Lefevre G, et al. Serious infectious events and immunoglobulin replacement therapy in patients with autoimmune disease receiving rituximab: a retrospective cohort study. Clin Infect Dis. 2021;72(5):727\u201337. https:\/\/doi.org\/10.1093\/cid\/ciaa127.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"730_CR21","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1002\/art.40937","volume":"71","author":"MY Md Yusof","year":"2019","unstructured":"Md Yusof MY, Vital EM, McElvenny DM, Hensor EMA, Das S, Dass S, et al. Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2019;71(11):1812\u201323. https:\/\/doi.org\/10.1002\/art.40937.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"730_CR22","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1002\/art.27555","volume":"62","author":"JE Gottenberg","year":"2010","unstructured":"Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(9):2625\u201332. https:\/\/doi.org\/10.1002\/art.27555.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"730_CR23","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1186\/ar3337","volume":"13","author":"HP Tony","year":"2011","unstructured":"Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kotter I, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther. 2011;13(3):R75. https:\/\/doi.org\/10.1186\/ar3337.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"730_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"730_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1001\/jama.2023.27885","volume":"331","author":"V Prasad","year":"2024","unstructured":"Prasad V. T-cell lymphoma from CAR T-cell therapy\u2014a new safety notice. JAMA. 2024;331(5):389\u201390. https:\/\/doi.org\/10.1001\/jama.2023.27885.","journal-title":"JAMA"},{"issue":"1","key":"730_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","volume":"26","author":"A Cordeiro","year":"2020","unstructured":"Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant. 2020;26(1):26\u201333. https:\/\/doi.org\/10.1016\/j.bbmt.2019.08.003.","journal-title":"Biol Blood Marrow Transplant"},{"key":"730_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102476","volume":"69","author":"R Greco","year":"2024","unstructured":"Greco R, Alexander T, Del Papa N, Muller F, Saccardi R, Sanchez-Guijo F, et al. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. EClinicalMedicine. 2024;69: 102476. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102476.","journal-title":"EClinicalMedicine."},{"issue":"6","key":"730_CR28","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909\u201320. https:\/\/doi.org\/10.1136\/ard.2010.144998.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"730_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2024","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83(1):30\u201347. https:\/\/doi.org\/10.1136\/ard-2022-223764.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"730_CR30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220920.","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"730_CR31","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMc2403705","volume":"390","author":"W Merkt","year":"2024","unstructured":"Merkt W, Lorenz HM, Schmitt M. CAR T-cell therapy in autoimmune disease. N Engl J Med. 2024;390(17):1628\u20139. https:\/\/doi.org\/10.1056\/NEJMc2403705.","journal-title":"N Engl J Med"},{"issue":"46","key":"730_CR32","doi-asserted-by":"publisher","first-page":"28950","DOI":"10.1073\/pnas.2012495117","volume":"117","author":"S Kobayashi","year":"2020","unstructured":"Kobayashi S, Thelin MA, Parrish HL, Deshpande NR, Lee MS, Karimzadeh A, et al. A biomimetic five-module chimeric antigen receptor ((5M)CAR) designed to target and eliminate antigen-specific T cells. Proc Natl Acad Sci USA. 2020;117(46):28950\u20139. https:\/\/doi.org\/10.1073\/pnas.2012495117.","journal-title":"Proc Natl Acad Sci USA"},{"key":"730_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jaut.2018.08.004","volume":"96","author":"L Zhang","year":"2019","unstructured":"Zhang L, Sosinowski T, Cox AR, Cepeda JR, Sekhar NS, Hartig SM, et al. Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II: peptide complex modulate the progression of autoimmune diabetes. J Autoimmun. 2019;96:50\u20138. https:\/\/doi.org\/10.1016\/j.jaut.2018.08.004.","journal-title":"J Autoimmun"},{"key":"730_CR34","doi-asserted-by":"crossref","unstructured":"Oh S, O'Connor K, Payne A. MuSK chimeric autoantibody receptor (CAAR) T cells for antigen-specific cellular immunotherapy of myasthenia gravis. Neurology. 2020;94(15_supplement).","DOI":"10.1212\/WNL.94.15_supplement.2769"},{"issue":"23","key":"730_CR35","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","volume":"186","author":"SM Reincke","year":"2023","unstructured":"Reincke SM, von Wardenburg N, Homeyer MA, Kornau HC, Spagni G, Li LY, et al. Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells. Cell. 2023;186(23):5084\u201397. https:\/\/doi.org\/10.1016\/j.cell.2023.10.001.","journal-title":"Cell"},{"issue":"7774","key":"730_CR36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","volume":"573","author":"H Aghajanian","year":"2019","unstructured":"Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, et al. Targeting cardiac fibrosis with engineered T cells. Nature. 2019;573(7774):430\u20133. https:\/\/doi.org\/10.1038\/s41586-019-1546-z.","journal-title":"Nature"},{"issue":"6576","key":"730_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tombacz I, Yadegari A, Mendez Fernandez PO, Shewale SV, Li L, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91\u20136. https:\/\/doi.org\/10.1126\/science.abm0594.","journal-title":"Science"},{"issue":"7814","key":"730_CR38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020;583(7814):127\u201332. https:\/\/doi.org\/10.1038\/s41586-020-2403-9.","journal-title":"Nature"},{"key":"730_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020287","author":"M Arjomandnejad","year":"2022","unstructured":"Arjomandnejad M, Kopec AL, Keeler AM. CAR-T regulatory (CAR-Treg) cells: engineering and applications. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10020287.","journal-title":"Biomedicines."},{"key":"730_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.934343","volume":"13","author":"T Riet","year":"2022","unstructured":"Riet T, Chmielewski M. Regulatory CAR-T cells in autoimmune diseases: progress and current challenges. Front Immunol. 2022;13: 934343. https:\/\/doi.org\/10.3389\/fimmu.2022.934343.","journal-title":"Front Immunol"},{"key":"730_CR41","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1742-2094-9-112","volume":"9","author":"M Fransson","year":"2012","unstructured":"Fransson M, Piras E, Burman J, Nilsson B, Essand M, Lu B, et al. CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J Neuroinflammation. 2012;9:112. https:\/\/doi.org\/10.1186\/1742-2094-9-112.","journal-title":"J Neuroinflammation"},{"issue":"5","key":"730_CR42","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1053\/j.gastro.2009.01.049","volume":"136","author":"E Elinav","year":"2009","unstructured":"Elinav E, Adam N, Waks T, Eshhar Z. Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology. 2009;136(5):1721\u201331. https:\/\/doi.org\/10.1053\/j.gastro.2009.01.049.","journal-title":"Gastroenterology"},{"key":"730_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.05.017","volume":"103","author":"M Tenspolde","year":"2019","unstructured":"Tenspolde M, Zimmermann K, Weber LC, Hapke M, Lieber M, Dywicki J, et al. Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. J Autoimmun. 2019;103: 102289. https:\/\/doi.org\/10.1016\/j.jaut.2019.05.017.","journal-title":"J Autoimmun"},{"issue":"5","key":"730_CR44","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/mt.2014.41","volume":"22","author":"D Blat","year":"2014","unstructured":"Blat D, Zigmond E, Alteber Z, Waks T, Eshhar Z. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol Ther. 2014;22(5):1018\u201328. https:\/\/doi.org\/10.1038\/mt.2014.41.","journal-title":"Mol Ther"},{"issue":"4","key":"730_CR45","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","volume":"9","author":"RK Das","year":"2019","unstructured":"Das RK, Vernau L, Grupp SA, Barrett DM. Naive T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. 2019;9(4):492\u20139. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1314.","journal-title":"Cancer Discov"},{"issue":"3","key":"730_CR46","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185\u201399. https:\/\/doi.org\/10.1038\/s41573-019-0051-2.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"730_CR47","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41422-022-00745-4","volume":"32","author":"S Castelli","year":"2022","unstructured":"Castelli S, Young RM, June CH. Off-the-shelf CAR T cells to treat cancer. Cell Res. 2022;32(12):1036\u20137. https:\/\/doi.org\/10.1038\/s41422-022-00745-4.","journal-title":"Cell Res"},{"issue":"11","key":"730_CR48","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu Y, Zhou Y, Zhang M, Zhao H, Wei G, Ge W, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022;32(11):995\u20131007. https:\/\/doi.org\/10.1038\/s41422-022-00721-y.","journal-title":"Cell Res"},{"key":"730_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003604","author":"MT Holzer","year":"2023","unstructured":"Holzer MT, Ruffer N, Huber TB, Kotter I, Ostendorf L, Krusche M. Daratumumab for autoimmune diseases: a systematic review. RMD Open. 2023. https:\/\/doi.org\/10.1136\/rmdopen-2023-003604.","journal-title":"RMD Open"},{"key":"730_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae144","author":"P Kvacskay","year":"2024","unstructured":"Kvacskay P, Merkt W. CD19.CAR-T cells versus obinutuzumab\u2014who will win the race on deep B cell depletion in systemic autoimmunity? Rheumatology (Oxford). 2024. https:\/\/doi.org\/10.1093\/rheumatology\/keae144.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00730-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-024-00730-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00730-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T09:07:57Z","timestamp":1724749677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-024-00730-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1007\/s40291-024-00730-0","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"assertion":[{"value":"8 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding was enabled and organized by Projekt DEAL. This work was supported by the Medical Faculty University Hospital Tuebingen\u2019s Clinician Scientist program Grant no. 477-0-0 awarded to Ann-Christin Pecher.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors A.C.P., L.H., C.L., and J.H. declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent (participation and publication)"}},{"value":"A.C.P., L.H., C.L., and J.H. contributed to the implementation of the existing research data and to the writing of the manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"The data that support the findings of this study are available on request from the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}